Pervasis Therapeutics, Inc. is developing biologically active therapeutics to address complex diseases and unmet medical needs. With this objective, the company has developed technologies to regulate vascular repair and restore blood flow to critical organs and vasculature. The flagship product, Vascugel®, which has undergone two Phase II clinical trials, is a cell-based therapeutic matrix developed to reestablish healthy vasculature after vascular injury. Vascugel® has the capability to be delivered in both open surgical and minimally invasive procedures. To date, Vascugel® has met all safety endpoints in clinical trials. Additionally, Pervasis is exploring broader indications in non-vascular applications.

Pervasis Therapeutics, Inc.
One Kendall Square, Ste. B6101
Cambridge, MA 02139-1663

617-621-3407
info@pervasistx.com

News Highlights

June 8, 2009

13th Annual Goldman Sachs Global Healthcare Conference - New York, NY

Private Company Forum 3:30 pm

Frederic Chereau; President and Chief Executive Officer, Pervasis Therapeutics, presented at the Goldman Sachs Global Healthcare Conference.

May 19, 2009

Pervasis Therapeutics Presents Promising Preclinical Data for its Minimally Invasive Cell Therapy at the European Association of Percutaneous Cardiovascular Interventions Annual Congress (EuroPCR) [ PDF ]

May 19-22, 2009

EuroPCR - Barcelona, Spain

Out-of-the-box innovations

“Percutaneous delivery of perivascular tissue engineered allogeneic endothelial cells minimizes intimal area and enhances vascular repair after endovascular peripheral interventions” presented by Helen Marie Nugent, Ph.D.; Co-Founder and Vice President, Research and Development, Pervasis Therapeutics

May 12, 2009

Pervasis Therapeutics to Present Preclinical Data on Novel, Minimally Invasive Cellular Therapy at the European Association of Percutaneous Cardiovascular Interventions Annual Congress [ PDF ]

May 5, 2009

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel® [ PDF ]

May 2009
Scientific American

"Progress in Tissue Engineering" [ PDF ]

January 14-16, 2009

Fifth International Conference on Cell Therapy for Cardiovascular Disease - New York, NY

“Vascular Restoration After Injury” presented by Helen Marie Nugent, Ph.D.; Co-Founder and Vice President, Research and Development, Pervasis Therapeutics

View more news